Financial Consulate Inc. Makes New Investment in Danaher Corporation $DHR

Financial Consulate Inc. bought a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,753 shares of the conglomerate’s stock, valued at approximately $744,000.

Other hedge funds have also bought and sold shares of the company. WFA of San Diego LLC bought a new position in Danaher in the 2nd quarter valued at $26,000. Howard Hughes Medical Institute purchased a new position in shares of Danaher in the 2nd quarter worth about $27,000. Red Tortoise LLC boosted its holdings in shares of Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after buying an additional 98 shares during the last quarter. Tripletail Wealth Management LLC bought a new position in Danaher during the third quarter valued at about $31,000. Finally, Heartwood Wealth Advisors LLC purchased a new stake in Danaher during the third quarter worth about $37,000. 79.05% of the stock is currently owned by institutional investors.

Insider Activity

In related news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. This represents a 13.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,248 shares of company stock worth $6,609,663 in the last three months. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $228.99 on Friday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The stock’s 50-day simple moving average is $223.65 and its 200 day simple moving average is $208.90. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a market capitalization of $161.75 billion, a price-to-earnings ratio of 47.21, a price-to-earnings-growth ratio of 4.43 and a beta of 0.89.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the prior year, the business posted $1.71 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. Morgan Stanley began coverage on shares of Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 target price for the company. Barclays increased their price objective on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Bank of America dropped their price target on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Finally, Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Twenty-one analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $248.25.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.